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Seizures are a prominent feature in N-Methyl-D-Aspartate receptor antibody (NMDAR
antibody) encephalitis, a distinct neuro-immunological disorder in which specific human
autoantibodies bind and crosslink the surface of NMDAR proteins thereby causing inter-
nalization and a state of NMDAR hypofunction. To further understand ictogenesis in this
disorder, and to test a potential treatment compound, we developed an NMDAR antibody
mediated rat seizure model that displays spontaneous epileptiform activity in vivo and
in vitro. Using a combination of electrophysiological and dynamic causal modelling techni-
ques we show that, contrary to expectation, reduction of synaptic excitatory, but not inhi-
bitory, neurotransmission underlies the ictal events through alterations in the dynamical
behaviour of microcircuits in brain tissue. Moreover, in vitro application of a neurosteroid,
pregnenolone sulphate, that upregulates NMDARs, reduced established ictal activity. This
proof-of-concept study highlights the complexity of circuit disturbances that may lead to
seizures and the potential use of receptor-specific treatments in antibody-mediated seizures
and epilepsy.
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Both in vivo and in vitro studies have clearly established thatthe pathogenic action of antibodies in N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is to
bind to the surface of the NMDARs, cross-link the proteins and
cause NMDAR internalization, resulting in a state of NMDAR
hypofunction1–3. As a result, the mainstay of treatment is
immunotherapy that aims to reduce the levels of circulating
neuronal autoantibodies or halt their production4,5. These treat-
ments can be slow to work, and carry the risk of harmful side-
effects as the healthy immune system is also compromised6. It is
clear that the reduction of NMDARs in NMDAR antibody
encephalitis causes a myriad of severe neurological symptoms,
and that reversal of this pathological effect in the acute and even
chronic stages of the disease has the potential to improve clinical
outcomes7–9. However, as yet, there are no immune-sparing
treatments that ameliorate the synaptic and circuit effects (psy-
chosis, ictogenesis) caused by the NMDAR hypofunction10,11.
The therapeutic potential of a receptor-specific treatment could
be particularly beneficial in children who are affected during
crucial developmental stages, marked by neuronal network plas-
ticity including that of the NMDAR subunits12,13. Indeed, studies
have found that after recovery children have persistent cognitive
problems and fatigue, resulting in lower academic achievement
and poorer quality of life14,15.
While neuropsychiatric features are the most common pre-
senting symptom of NMDAR antibody encephalitis, acute
symptomatic seizures and encephalopathic electroencephalogram
(EEG) changes are essential clinical and investigative features in
patients of all ages16. Seizures present as part of the disease course
in >80% of patients and EEG changes are seen in >95%, more
commonly than Magnetic Resonance Imaging (MRI) brain
changes, as noted repeatedly in cohort and case studies4,5,17.
Despite the symptom predominance of seizures in humans,
producing reliable and consistent spontaneous seizure animal
models of this disorder using passive transfer of human-derived
antibodies is challenging18–20. In our previous passive transfer
mouse model, we demonstrated increased in vivo seizure sus-
ceptibility (and therefore network hyperexcitability) 48 h after
intracerebroventricular NMDAR antibody injection compared to
controls, however spontaneous seizures were not seen18,21.
Importantly, seizures within the context of NMDAR antibody
encephalitis do not respond well to standard anti-seizure medica-
tions, as seen in other forms of antibody-mediated encephalitis22–24.
Given the specific involvement of the excitatory NMDAR, it is
tempting to speculate that the pathophysiology of these epilepsies
diverges from a simple ‘excitation-inhibition’ imbalance and that an
NMDAR-specific treatment may be more effective in minimizing
acute symptoms such as seizures, and could potentially be given
alongside immunotherapy to achieve more rapid symptomatic relief.
This study aimed to understand the causative changes in synaptic
physiology contributing to NMDAR antibody-mediated seizures, and
to explore the unmet clinical need for receptor-specific treatment. We
developed a juvenile Wistar rat model of NMDAR antibody ence-
phalitis, in which NMDAR antibodies derived from human patients
were used to induce a robust and repeatable seizure phenotype.
Combining in vitro, in vivo, and in silico approaches we have
demonstrated that, counterintuitively, the epileptic dynamics emerge
from reductions in excitatory neurotransmission caused by NMDAR
antibodies, and provide proof-of-concept in vitro evidence of a
NMDAR specific neurosteroid rescue treatment both in the rodent
model, and in human epileptic brain tissue.
Results
NMDAR antibodies bind specifically to Wistar rat brain tissue.
All three NMDAR antibody preparations derived from patients
with the disease bound specifically to rodent hippocampus
(Supplementary Fig. 1) confirming previous studies in mice3,8,18.
The florescence intensities of NMDAR antibody injected and
infused brain slices were significantly higher than those measured
after injection or infusion of control human IgG or non-brain
reactive monoclonal antibodies (mGO53, 12D7) (Supplementary
Fig. 1).
NMDAR antibodies cause spontaneous epileptiform activity
in vitro. In order to characterize NMDAR antibody induced
abnormalities of synaptic transmission and circuit dysfunction,
we first examined the effects of the antibody preparations on
brain-slices in vitro. At 48 h after intracerebroventricular (ICV)
injection, juvenile rats injected with NMDAR antibodies exhib-
ited sustained and repetitive hyperexcitable behaviour including
myoclonic twitches, jerks and jumps (Supplementary Movie 1).
Animals were sacrificed at this time-point and brain slices were
prepared for in vitro electrophysiology studies. These hippo-
campal local field potential (LFP) recordings showed significantly
more frequent spontaneous epileptiform activity in NMDAR
antibody injected slices compared to slices prepared from control
antibody injected animals (Fig. 1a–d). In the NMDAR antibody
injected animals the number of interictal events was higher in the
CA3 hippocampal region compared to CA1, with reduced
interevent interval (IEI) between spikes (Fig. 1e, f).
To determine the synaptic changes contributing to this
apparent circuit hyperexcitability, whole-cell patch clamp record-
ings were made from pyramidal cells in the CA3 region of the
hippocampus (Fig. 2a; cell morphology confirmed on post-hoc
analysis, Supplementary Fig. 1). There was a reduction in the
frequency and amplitude of spontaneous excitatory post-synaptic
current (sEPSC) recordings (Fig. 2b–d) and a significant shift
towards a faster decay time indicating loss of NMDAR-mediated
events (Fig. 2e, f). By contrast, no changes were seen in the
frequency or amplitude of spontaneous inhibitory post-synaptic
currents (sIPSCS) or miniature IPSCs (Fig. 2g–l). Additionally,
evaluation of the excitability and intrinsic properties of recorded
CA3 pyramidal neurons showed them to be hyperexcitable
(Fig. 2m–p). Together these results indicate that local hippo-
campal networks are hyperexcitable when recorded in vitro 48 h
after a single ICV injection of NMDAR antibodies in vivo. This
circuit hyperexcitability is paradoxically associated with a
reduction of excitatory neurotransmission in CA3 induced by
the NMDAR antibodies with compensatory changes in the
intrinsic properties of recorded CA3 pyramidal cells.
NMDAR antibodies cause spontaneous epileptic seizures
in vivo. To demonstrate ictogenesis in vivo, 7-day osmotic pumps
were used to deliver NMDAR antibodies or control antibodies
into the lateral cerebral ventricles of juvenile Wistar rats (n= 6
animals for each group). Following the observations above, a
depth electrode was placed in the CA3 region. Spontaneous
epileptiform events were observed in the NMDAR antibody
infused animals in vivo and evident in the EEG tracings (Fig. 3a,
Supplementary Movies 2–4). A significant increase in EEG
coastline of the NMDAR antibody animals compared to control
antibody treated reflected this increase in occurrence of epi-
leptiform high amplitude events (Fig. 3b). Using automated sei-
zure detection18,25, we observed a significant increase in the
number of ictal events per hour in the NMDAR antibody animals
compared to controls. The maximum ictal event frequency was
seen in NMDAR antibody animals during Day 2 of the infusion,
but it remained significantly elevated compared to controls until
the end of the recording and infusion (Fig. 3c–e). The EEG of
NMDAR antibody animals exhibited increased power in all
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Fig. 1 Hippocampal local field potential recordings in vitro 48 h after intracerebroventricular injection of NMDAR antibodies show spontaneous
epileptic activity, highest in the CA3 region. a Example traces of local field potential brain slice recordings from control (ai) and NMDAR antibody (aii–iv)
injected animals after 48 h from the CA3 region. Scale bar 100 µV vs. 15 s (i and ii), 100 µV vs. 2 s (iii) and 50 µV vs. 250msec (iv). b Example traces of
local field potential brain slice recordings from control (bi) and NMDAR antibody (bii–iv) injected animals after 48 h from the CA1 region. Scale bar 100 µV
vs. 30 s (I and ii), 50 µV vs. 5 s (iii) and 50 µV vs. 500msec (iv). c The number of spikes (interictal events) per 15 min in the NMDAR antibody slices
compared to controls (Control (n= 8 brain slices) vs. NMDA (n= 11 brain slices); **p= 0.0065, Mann–Whitney). d The intervent interval (IEI) in control
Ab slices compared to NMDAR antibody injected slices (Control (n= 8 brain slices) vs. NMDA (n= 11 brain slices); ***p < 0.001, Mann–Whitney). e The
number of spikes (interictal events) in the CA3 region of the NMDAR antibody hippocampal slices as compared to CA1 (NMDA CA1 (n= 6 brain slices) vs.
NMDA CA3 (n= 5 brain slices); ***p < 0.001, Mann–Whitney). f Comparison of IEI between the CA3 and CA1 region in NMDAR antibody hippocampal
slices (NMDA CA1 (n= 6 brain slices) vs. NMDA CA3 (n= 5 brain slices); ***p < 0.001, Mann-Whitney). Measurements expressed as mean ± standard
error of the mean (SEM).
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frequency bands measured compared to control antibody animals
(1–4 Hz, 4–8 Hz, 8–12 Hz, 12–30 Hz, 30–50 Hz, 50–70 Hz,
70–120 Hz, and 120–180 Hz; p= <0.0001, Mann–Whitney). The
greatest increase in power, seen in the 12–30 Hz range (676 ± 151
vs 3195 ± 102, n= 6; p= <0.0001, Mann–Whitney), was similar
to the typical excessive beta activity observed in EEGs of NMDAR
antibody patients (14–20 Hz)26.
To confirm that these findings were concordant with the in vitro
findings at 48 h, we recorded LFPs in hippocampal brain slices at
the completion of the recording experiments (ranging from day 7
to 14). In line with the spontaneous epileptiform activity seen
in vivo, there was a considerable increase in the number of
interictal events and a reduced IEI of ictal spikes in NMDAR
antibody infused animals compared to controls (Fig. 3f, g). CA3
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hippocampal whole-cell patch clamp experiments in NMDAR
antibody treated animals showed an even further increase in the
IEI of sEPSCs (Fig. 3h), and further reduction of the amplitude
(Fig. 3i) from that seen at 48 hours. Thus a reduction in excitatory
neurotransmission was found to be coincident with the sponta-
neous epileptic events in both the 48 h and 7 day NMDAR
antibody models.
Reduced excitatory neurotransmission contributes to EEG
changes. We tested whether the in vitro changes in single neuron
behaviour associated with NMDAR antibody contributed to in vivo
(interictal) EEG patterns by using a computational model of
microcircuit dynamics. Specifically, we tested the hypothesis that the
microscale recordings can inform models of LFP dynamics using
Bayesian model comparison of models with, and without prior
information derived at the microscale. We first generated quantitative
predictions of the population-level effect of NMDAR antibody based
on in vitro differences between NMDAR antibody and control
antibody exposed neurons measured using whole-cell patch clamp
recordings (Fig. 4a, b). We then fitted a four-population neural mass
model (the canonical microcircuit27) to EEG power spectral densities,
first for control animals, then for NMDAR antibody animals under
different empirical priors with model fits for the power spectral
densities shown for the final, selected model in Fig. 5a. These
empirical priors were based on posteriors from the control antibody
treated animals and, for subsets of parameters, the quantitative pre-
dictions made from the in vitro recordings (see Methods). We then
performed Bayesian model comparison of these models using a free
energy approximation of the model evidence – briefly, we fitted
models where different subsets of parameters were informed by the
microscale priors to the same data. By comparing the model evidence
across these model inversions, we can thus evaluate whether the
microscale priors allow a more parsimonious explanation for the LFP
data we have fitted. Given the uneven distribution of NMDAR in the
cortical layers and across different neuronal populations, we also
compare models where priors are applied only to different subsets of
parameters, resulting in the model space of 22 models. This com-
parison provides two key insights: (i) the model equipped with the
full set of quantitative predictions from the microscale provides a
more parsimonious explanation for the observed EEG spectral dif-
ferences between control antibody and NMDAR antibody, compared
to a null model without these microscale-derived predictions; and (ii)
in a model space comparing models with only subsets of parameters
informed by microscale-derived priors, the best model incorporates
microscale-derived priors only for amplitude and population variance
in one compartment of the canonical microcircuit model.
We then considered the overall winning model highlighted in
Fig. 4c and used its posterior parameters as priors for fitting EEG
power spectral densities for seizure recordings. This modelling
approach thus provided us with a parameter set capturing the
difference between interictal EEG spectra in NMDAR antibody
and control antibody treated animals (Fig. 4d, middle panel), and
between ictal EEG spectra and interictal EEG spectra in NMDAR
antibody (Fig. 4d, bottom panel). In order to assess whether the
two main effects of interest (changes caused by NMDAR
antibody, and changes induced by seizures) can be separated in
terms of their associated parameter changes, we performed a
principal component analysis over three vectors containing the
parameters fitted to control antibody, NMDAR antibody
(interictal), and NMDAR antibody (ictal) states. Projecting the
parameter combinations for each of the three states onto the first
two principal components (Fig. 4e) demonstrates separability of
the two effects with near orthogonal effects of NMDAR antibody
and seizure onset. For subsequent analyses, we therefore
considered these effects independently: (i) the synaptic parameter
difference derived from control antibody and NMDAR antibody
(interictal) conditions captures the main effect of NMDAR
antibody infusion, which we know from the preceding results in a
higher seizure likelihood, and is thus epileptogenic in the animals
(hence, ‘epileptogenesis parameters’ for brevity). (ii) The synaptic
parameter difference derived from the NMDAR antibody
(interictal), and the NMDAR antibody (ictal) conditions captures
the main effect of transition into the seizure state, and thus
represents ictogenesis (hence, ‘ictogenesis parameters’ for
brevity).
NMDAR antibodies push brain microcircuits into an unstable
regime. Our hypothesis was that NMDAR antibody alter brain
dynamics in a way that makes neuronal circuits more susceptible
to potentially seizure-inducing fluctuations in synaptic para-
meters. We tested this using the neuronal microcircuit models in
simulation mode, allowing us to test any combination of
Fig. 2 Whole-cell patch-clamp recordings from hippocampal CA3 pyramidal cells in vitro 48 h after intracerebroventricular injection of NMDAR
antibodies show a reduction in excitatory but not inhibitory synaptic neurotransmission and intrinsic hyperexcitability. a Representative spontaneous
EPSC (sEPSC) whole-cell patch clamp recordings 48 h after injection with NMDAR antibodies or control antibodies. Scale bar 10 pA vs. 5 s. b The
interevent interval (IEI) of sEPSCs recorded from CA3 pyramidal cells in NMDAR antibody injected rodent slices (n= 18 cells) compared to control Ab
(n= 8 cells) injected slices (**p= 0.003, Mann-Whitney). c The amplitude of the sEPSCs in CA3 pyramidal cells recorded from NMDAR antibody injected
slices (n= 18 cells) compared to controls (n= 8 cells) (*p= 0.04; Mann-Whitney). d Representative average sEPSCs recorded from NMDAR antibody
injected slices as compared to control antibody injected slices. Scale bar 10 pA vs. 10ms. e Cumulative frequency plot showing reduced decay time of
sEPSCs recorded from NMDAR antibody slices as compared to the controls (n= 7 cells in each group). f Decay time of the sEPSCs in the NMDAR
antibody injected rodent slices as compared to the controls (n= 7 cells in each group; p= <0.001, Mann–Whitney). g Representative whole-cell patch
clamp recording of spontaneous IPSC (sIPSC) from CA3 pyramidal cells after injection of NMDAR- or control antibodies. Scale bar 10 pA vs. 5 s. h The
intervent interval of the sIPSCs recorded from CA3 pyramidal cells in control and NMDAR antibody injected slices (n= 6 cells in each group; p= 0.156,
Mann–Whitney). i The amplitude of sIPSCS recorded from the control and NMDAR antibody injected slices (n= 6 cells in each group; p= 0.15,
Mann–Whitney). j Representative average sIPSCs recorded from NMDAR antibody injected slices as compared to control antibody injected slices. Scale
bar 5 pA vs. 10 ms. k The interevent interval of miniature IPSCs recorded (in the presence of TTX 1 µM) from pyramidal cells in CA3 in control and NMDAR
antibody injected slices (n= 6 cells in each group; p= 0.28, Mann–Whitney). l The amplitude of miniature IPSCs recorded (in the presence of TTX 1 µM)
from pyramidal cells in CA3 in control and NMDAR antibody injected slices (n= 6 cells in each group; p= 0.41, Mann–Whitney). m Representative traces
of CA3 pyramidal cell responses during depolarising current steps in CA3 pyramidal cells from control and NMDAR antibody injected rodent slices.
n Depolarising steps of different current intensities elicited significantly more spikes in the NMDAR antibody injected rodent slices (n= 15 cells) than in
control antibody (n= 15 cells) treated slices (**p= 0.005, unpaired t-test). o The resting membrane potential was significantly depolarised in the NMDAR
antibody treated (n= 14 cells) CA3 pyramidal cells compared to those treated with control antibody (n= 13 cells; ***p= <0.0001, Mann–Witney). p Input
resistance was not significantly altered between the two conditions (NMDAR antibody, n= 14 cells vs. control antibody n= 15 cells; p= 0.34,
Mann–Witney). Measurements expressed as mean (M) ± standard error of the mean (SEM).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02635-8 ARTICLE
COMMUNICATIONS BIOLOGY |          (2021) 4:1106 | https://doi.org/10.1038/s42003-021-02635-8 | www.nature.com/commsbio 5
Fig. 3 In vivo spontaneous epileptic EEG activity recorded in rodents infused with NMDAR antibodies. a Example EEG recordings from experimental
rodents using wireless EEG transmitters with osmotic pumps in situ delivering control or NMDAR antibodies. b EEG coastline length (calculated per second
for the total 7 day recording period for each animal) in NMDAR antibody animals as compared to control animals (n= 6 animals in each group;
***p < 0.0001, Mann–Whitney). c The number of spontaneous ictal events/hour (mean median ± SEM) in the NMDAR antibody animals compared to
controls (***p < 0.001; Mann–Whitney). d Graph illustrating median number of ictal events over time of control and NMDAR antibody infusion. e Daily
comparison of ictal events in the NMDAR antibody and control antibody animals (***p= <0.001, two-way Anova with Bonferroni correction). f Ictal spike
counts from hippocampal LFP measurements in brain slices prepared from NMDAR antibody and control antibody infused animals at the end of the in vivo
EEG recording period (controls (n= 7) vs. NMDA (n= 38); ***p < 0.001, Mann–Whitney. g Interevent interval from hippocampal LFP measurements in
brain slices prepared from NMDAR antibody and control antibody infused animals at the end of the in vivo EEG recording period (controls (n= 7 brain
slices) (12.56 ± 2.70) vs. NMDA (n= 38 brain slices); ***p < 0.001; Mann–Whitney). h Interevent interval of sEPSCs recorded from putative CA3 cells in
slices prepared from animals after 7 days of NMDAR antibody (n= 15 cells) as compared to the same measurements taken at 48 h after NMDAR antibody
infusion (n= 18 cells) (*p= 0.03; Mann–Whitney). i Amplitude measurements of sEPSCs recorded from putative CA3 cells in slices prepared from animals
after 7 days of NMDAR antibody (n= 15 cells) as compared to the same measurements taken at 48 h after NMDAR antibody infusion (n= 18 cells)
(*p= 0.03; Mann–Whitney). Measurements expressed as mean (M) ± standard error of the mean (SEM).
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parameter values, including mixtures of the three empirically-
fitted conditions. Specifically, we ran simulations across an ‘epi-
leptogenesis’ × ‘ictogenesis’ parameter space. For this analysis, we
consider the parameter differences between control and NMDAR
antibody (interictal) condition the ‘epileptogenesis’ parameters
since they capture the difference between brain dynamics in the
non-epileptic control animals and the animals with NMDAR
antibody induced spontaneous recurrent seizures. Similarly, we
consider the parameter differences between NMDAR antibody
(interictal) and NMDAR (ictal) the ‘ictogenesis’ parameters since
they capture the difference between brain dynamics in the
interictal and ictal state. We derived initial parameterisations by
fitting microcircuit models to the three empirically observed brain
states as described above (control antibody, interictal NMDAR
antibody and seizure NMDAR antibody; model fits shown in
Fig. 5a). We then simulated linearly spaced intermediate steps
between states along this 2-dimensional parameter space. At each
point, we simulated the full spectrum, and classified it into one of
the three empirically observed brain states by least mean squared
difference between the simulated and observed spectra (Fig. 5b).
Fig. 4 In vitro microscale disruptions of excitatory neurotransmission explain NMDAR antibody-associated in vivo neurophysiological changes.
a In vitro recordings of sEPSCs were used to quantify differences between control antibody and NMDAR antibody related neurotransmission, including
half-life and amplitude of EPSCs. We also estimated EPSC homogeneity by fitting a sigmoid curve to the cumulative frequency of EPSC amplitudes, where
the slope at the midpoint increases with more homogeneous EPSC amplitude distribution. b Microscale data features map onto population parameters in a
canonical microcircuit model consisting of two layered neuronal oscillator pairs with recurrent excitation-inhibition coupling. Key synaptic parameters of
this model are population synaptic response amplitude, time constant and response sigmoid, which are affected by EPSC amplitude, time constant, and
amplitude distribution, respectively. Using the dynamic causal modelling framework, we fit a single such microcircuit to local field potential recordings in
control Ab and NMDAR antibody exposed mice. c Bayesian model comparison is shown for inverted models of NMDAR antibody (interictal) local field
potential dynamics where subsets of the excitatory synaptic parameters were informed by priors derived from microscale recordings. There is decisive
evidence that the full model, where all parameters had microscale-informed priors, provides a more parsimonious explanation for the data than the model
without predictive priors (BF ~ΔF’= 3.9). Of all tested models, the model containing predictive priors only for amplitude (γ) and population variance (σ),
and only for the slow neuronal oscillator populations (inhibitory interneurons and deep pyramidal cells) performed best (BF ~ΔF’=3.9) with a posterior
probability of >95% in the given model space. d Parameter differences between conditions are shown for control vs. interictal NMDAR antibody-associated
dynamics (predicted NMDAR-Ab effect; main effect of NMDAR-Ab: estimated in the winning model), and seizure vs. interictal NMDAR antibody dynamics
(main effect of seizure: estimated). Error bars indicate a Bayesian 95% credible interval. Darker shading parameters where the estimated difference
exceeds the credible interval. e A principal component decomposition of the full parameter set across three states (control antibody, NMDAR antibody
(interictal), and NMDAR antibody (seizure)) shows separability of the main effects of antibody (with most of the difference along the first principal
component) and seizure onset (with most of the difference along the second principal component).
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This map of parameter space shows that for microcircuits at
control antibody parameterization, the transition to a putative
seizure-like territory is further away on the ‘ictogenesis’ para-
meter axis than it is for microcircuits at the interictal NMDAR
antibody parameterization. Each of the territories is characterised
by particular spectral features, illustrated in Fig. 5c by a map of
high frequency and low frequency amplitude ratios across the
same parameter space.
To evaluate sensitivity of these microcircuits to changes in the
ictogenicity parameters, we quantified the difference of each
simulated spectrum to spectra simulated from similar, ‘neigh-
bouring’ ictogenicity parameter values (Fig. 5d). This analysis
revealed that the NMDAR antibody interictal state is most
sensitive to small changes in ictogenicity parameters.
Spectral changes associated with the increasing effect of
ictogenicity parameters are further shown in Fig. 5e, relative to
Fig. 5 NMDAR antibody pushes neuronal microcircuits towards unstable regimes. a Power spectra of LFP recordings of control antibody injected mice,
and interictal and ictal states of NMDAR antibody injected mice are fitted with neural mass models of neuronal microcircuits. Dashed lines represent the
model fit; solid lines represent the empirically measured spectra, indicating faithful reproduction of empirically measured spectral features in the fitted
dynamic causal model. b Based on the parameters derived from the dynamic causal model fits (represented here by circles), parameter changes that
capture NMDAR antibody associated alterations in microcircuitry (‘epileptogenicity’) and seizure onset transition (‘ictogenicity’) were identified (arrows).
Linear combinations of these parameters are then used to simulate spectra at different locations in a two-dimensional parameter space along both
‘epileptogenicity’ on the y-axis, and ‘ictogenicity’ on the x-axis. At each point full spectra were generated, and classified as one of three possible states
(‘Control antibody-like’, ‘NMDAR antibody interictal-like’, ‘NMDAR antibody seizure-like’) based on the smallest mean-squared difference to the three
empirically measured spectra. Insets show example simulations (normalized to the ‘Control antibody’ spectrum, indicated by the black line) at three
different values for ‘epileptogenicity’ indicated by the red arrow heads (10%, 50%, 90% towards full ‘epileptogenicity’ parameter change). Each line
represents a simulation at different ictogenicity values spanning the full width of ictogenicity parameters, colour-coded by their classification. c Along the
‘epileptogenicity’ vs.’ictogenicity’ parameter space, the ratio of high frequency (>20 Hz) and low-frequency (<8 Hz) log amplitude is shown with state
separating boundaries from panel (b) overlaid. d This plot demonstrates sensitivity to changes in ictogenicity parameters. For each given ‘epileptogenicity’
(i.e. row in the parameter space plot), mean-squared differences between neighbouring values of ‘ictogenicity’ are shown along the log-scale (a.u.) colour
axis. State separating boundaries from (b) are overlaid. There is considerable overlap between regions in parameter space, where the microcircuit is
sensitive to perturbation, and the NMDAR antibody-like state identified in (b). e To demonstrate differences in sensitivity to ‘ictogenicity’ parameter
changes, spectral differences from both control Ab parmeterisation and NMDAR Ab parameterisation are shown for increasing contribution of
‘ictogenicity’ parameters.
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control antibody and interictal NMDAR antibody microcircuit
parameterisations.
Pregnenolone sulphate (PregS) rescues NMDAR antibody
epileptic changes in vitro. We hypothesised that increasing
NMDAR expression could rescue the electrophysiological features
associated with NMDAR antibody. The neurosteroid pregneno-
lone sulphate (PregS) has a membrane delimited action to
increase the trafficking of functional NMDARs to the neuronal
membrane28. Using whole-cell patch clamp recordings of sEPSCs
from untreated Wistar rat hippocampal slices we showed that
PregS significantly increased amplitude and frequency of sEPSCs;
the increased frequency was reversed by application of the
NMDAR antagonist MK801 confirming NMDAR mediated effect
(Supplementary Fig. 2a–d). PregS reduced sIPSC IEI (162 ± 47.5
vs 101 ± 36.7, n= 9 cells; p= 0.03, Wilcoxon paired rank test),
but did not affect the amplitude (22.81 ± 2.5 vs 30.90 ± 3.2, n= 9
cells; p= 0.25, Wilcoxon paired rank test) in control slices.
Next we tested whether these effects would rescue the NMDAR
antibody induced abnormalities observed in vitro. We recorded
LFP discharges in vitro before and after addition of PregS to brain
slices from animals treated with NMDAR antibody or control
antibody for 48 h or 7 days (Fig. 6a). The number of interictal/
spike events in NMDAR antibody treated slices was significantly
reduced after application of PregS and there was a corresponding
increase in IEI (Fig. 6b,c). By contrast, slices from rats treated
with control antibody showed no significant reduction in
interictal events after application of PregS, although the IEI did
show a measurable reduction post PregS (Fig. 6b, c).
We confirmed that the reduction in LFP spiking activity was
associated with a rescue of the synaptic abnormalities by
performing whole-cell patch clamp recordings in hippocampal
slices from animals exposed to short (48 h) or more chronic
(7 days) NMDAR antibody exposure. In both conditions, PregS
increased the frequency of sEPSCS recorded in CA3 neurons
from NMDAR antibody treated animals back to control levels (as
measured by a fall in IEI; Fig. 7a, b). There was no significant
effect of PregS on sEPSC amplitude (15.2 ± 0.93 vs 14.5 ± 1.3,
n= 12; p= 0.5, Wilcoxon ranked pairs test), mini-IPSC ampli-
tude (18.9 ± 4.1 vs 15.9 ± 2.6 pA, n= 6 in both groups; p= 0.15,
Wilcoxon ranked pairs test) or mini IPSC IEI (200 ± 39 vs
60.2 ± 69.3 ms, n= 6 in both groups; p= 0.22, Wilcoxon ranked
pairs test).
Finally, we showed that this acute reversal of NMDAR
antibody mediated electrophysiological effects by PregS could in
principle be translated to human brains. Paediatric brain slices
prepared from tissue resected during epilepsy surgery (Fig. 7c)
was exposed to PregS. As in the rat brain slices, we saw a similar
increase in the frequency of sEPSCs (i.e. reduction of IEI of
sEPSCs) but no effect on the sEPSC amplitude (Fig. 7d, e). There
was also no significant change in the sIPSCS amplitude after
addition of PregS to human tissue (31.87 ± 9.7 vs 27.96 ± 4.1,
n= 6; p= 0.44, Wilcoxon paired rank test), or in the IEI
(123 ± 41.8 vs 95.7 ± 15.8; p= 0.09, Wilcoxon paired rank test).
Discussion
NMDAR antibodies disrupt normal brain circuit function and are
associated with a range of neurological symptoms in patients,
including epileptic seizures. The majority of these symptoms are now
understood to be directly caused by antibody-induced hypofunction
of the excitatory NMDAR. However, the link between reduced
NMDAR function and increased seizure propensity has remained
unexplained, and is particularly counterintuitive from a classical
perspective of seizures arising from an excitatory-inhibitory
imbalance29. Combining electrophysiological recordings in a rat
model of NMDAR antibody encephalitis and computational mod-
elling of brain microcircuit function, we show that an effective
reduction in excitatory synaptic neurotransmission observed at the
single-neuron scale underlies NMDAR antibody epileptogenesis by
altering the dynamical makeup of brain microcircuitry, making it
more susceptible to excursions into pathological brain states. We
fitted synaptic parameters of microcircuit models to spectral features
of LFP data in different experimental conditions corresponding to a
non-epileptic, interictal condition (control), an epileptic and interictal
condition (NMDAR antibody interictal) and an epileptic and ictal
condition (NMDAR-ictal). This allowed the separation of two main
effects—epileptogenesis, and ictogenesis. In terms of parameter space,
these effects were separable, meaning that they acted on different
subsets of synaptic parameters. The transition from interictal to ictal
state (i.e. ictogenesis) was best explained by changes in synaptic
coupling that effectively push excitation-inhibition out of balance into
a hyperexcitable state. Yet the pathophysiological process of epi-
leptogenesis—i.e. the synaptic changes that render the brain more
likely to undergo an interictal-ictal transition—are separable from
those associated with ictogenesis. In fact, in our particular animal
model we can show that the hypoexcitation induced by NMDAR
antibody counterintuitively contributes to epileptogenicity, by
increasing the sensitivity of microcircuits to fluctuations of the icto-
genicity parameters. We demonstrate that this phenotype can be
rescued with the neurosteroid, PregS, which, among other pharma-
cological actions, is known to increase NMDAR availability at the
neuronal membrane. Furthermore, we reproduced the synaptic effect
of PregS in human brain tissue in vitro, indicating its potential use as
precision-treatment for epileptic seizures in patients with established
NMDAR antibody encephalitis and potentially other seizure aetiol-
ogies associated with NMDAR-hypofunction.
The genetic background of rodent models can confer different
levels of seizure susceptibility30,31. Juvenile Wistar rats are highly
seizure susceptible at P2132 and proved to be an effective choice
for this passive transfer NMDAR antibody-mediated seizure
model. The CA3 region was found to have the most spontaneous
epileptic activity after NMDAR antibody ICV injection, and
epileptic discharges were therefore recorded from this location
in vivo. The CA3 hippocampal region is also the seizure-onset
zone in other murine models of epilepsy33,34. Another study
using NMDAR antibody positive CSF recorded a higher inci-
dence of CA3 epileptiform afterpotentials in brain slices from
Wistar rats injected with NMDAR antibodies compared to
controls35; these epileptiform events were not seen in other hip-
pocampal areas36,37. Furthermore, electrophysiology studies with
leucine-rich-glioma-1 autoantibodies (LGI1 antibodies), that
cause facio-brachial dystonic seziures and limbic encephalitis,
enhanced CA3 pyramidal cell excitability when applied
in vitro38,39, and patients show focal CA3 subfield atrophy on 7T
MRI following LGI1 antibody-mediated disease40. Together, these
reports and our results confirm that the CA3 subfield is an
important epileptogenic hippocampal region in immune-
mediated types of epilepsy, justifying its further investigation.
Almost all healthy brains can produce epileptic seizures in the
context of acute excitation-inhibition imbalance, such as acute
GABA-blockade caused by chemoconvulsants41. Furthermore,
many effective anti-seizure drugs aim to restore this balance by
increasing levels of inhibition or reducing neuronal excitation42.
Hypofunction in both excitatory AMPAR and NMDA receptors
have been reported in epilepsies and seizure models, including
antibody-induced loss of AMPARs43,44. Similarly, recent work in
a rat model of chronic temporal lobe epilepsy (TLE) demonstrates
that dysfunctional regulation and resultant hypofunction of GluA
(AMPAR) subunits is an important factor in epileptogenesis45.
Defects in another AMPAR subunit, GluA2, are also found in
neurodevelopmental disorders such as epileptic encephalopathy
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in children46. Previous experiments have also demonstrated that
the weakening of excitatory synapses has a paradoxical effect on
neural networks, with one early in vitro and computational study
showing use of AMPAR blockers (CNQX) at moderate con-
centrations evoked seizure-like activity47 and, more recently,
AMPAR antibodies being demonstrated to produce weakened
excitatory and inhibitory transimission and increased intrinsic
excitability48 similar to the effects demonstrated here with
NMDAR antibodies. In fact, early experiments showed epileptic
seizures can be sustained even when measured extracellular cal-
cium reached levels that would completely block chemical
synaptic transmission49 highlighting the role of nonsynaptic
neural network properties in epileptogenesis. Finally, as the
Turrigiano laboratory has shown, synaptic scaling of excitatory
amino acid receptors is co-regulated alongside intrinsic
excitability48 through the actions of CaMKIV, but GABA inhi-
bition is separately regulated, emphasising the interdependence of
synaptic, cellular and circuit mechanisms in control of network
excitability50.
That NMDAR hypofunction is proconvulsant has been shown
though a variety of approaches. Genetically modified mice lacking
NMDARs in CA3 pyramidal neurons were more susceptible to
kainate-induced seizures, and pharmacological blockade of CA3
NMDAR in adult wild-type mice produced similar results51. Loss
of function mutations in both the GluN1 and GluN2A subunits of
the NMDAR have been identified in patients with epilepsy and
Fig. 6 Pregnenolone sulphate reduces NMDAR antibody mediated spontaneous ictal activity in vitro. a Representative in vitro slice LFP recording
(subpanel ai) from a 7-day NMDAR antibody treated animal illustrates the response to PregS 100 µM. Scale bar 10µV vs. 5 mins. Subpanels a(ii) and a(iii)
represent the magnification of control and PregS 100 µM trace area respectively. Scale bars 50 µV vs. 5 s. b Ictal spike counts after PregS is applied to
control antibody infused slices (n= 6 slices; p= 0.07, Wilcoxon paired rank test) and NMDAR antibody infused slices (n= 45 slices; *p < 0.05, Wilcoxon
paired rank test). c IEI recorded in the control Ab infused LFP slices after addition of PregS indicates an increased frequency of events (n= 6 slices;
p < 0.001, Wilcoxon paired rank test). The frequency of events is reduced in the NMDAR antibody slices after addition of PregS (n= 36 slices; ***p < 0.001;
Wilcoxon paired rank test). Measurements expressed as mean (M) ± standard error of the mean (SEM).
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neurodevelopmental disorders52,53. A recent dynamic causal
modelling study of NMDAR antibody encephalitis patient EEGs
also showed that the deficit in signalling at NMDARs in patients
with NMDAR antibody encephalitis was predominantly located
at the NMDA receptors of excitatory neurons rather than at
inhibitory interneurons54, as shown here in our model. By
combining detailed multiscale electrophysiology and computa-
tional modelling, we provide further evidence that the direct
synaptic effects of NMDAR antibody identified from whole-cell
patch clamp recordings offer a quantitative explanation for the
epileptic brain dynamics captured in vivo using local field
potentials.
In our circuit models of NMDAR antibody-induced epilepto-
genesis, the parameter changes required to optimally model the
associated LFP changes required not only changes in NMDAR-
transmission related parameters, but also more widespread
changes involving both excitatory and inhibitory neuronal
populations. This would appear to fit with the co-dependent
changes seen in our rodent model and those of others as reported
above. In addition to such compensatory and maladaptive net-
work changes, heterogeneity of NMDAR distribution at normal
baseline function may also account for the unexpected effect of
NMDAR-hypofunction in neuronal circuit dynamics. Selective
forebrain pyramidal neuron NR1 knockout mice demonstrated
both socio-cognitive deficits and increased pyramidal cell
excitability55, potentially driven by a release from inhibition by
reducing putative NMDAR-mediated excitatory driving of inhi-
bitory neuron activity, or by changing phase relationships
between interacting neuronal populations. Similarly, hippo-
campal CA3 NMDA receptors may normally act to suppress the
excitability of the recurrent network by restricting synchronous
firing of CA3 neurons51, with NMDAR-blockade releasing them
from this suppression. Our modelling also suggests that NMDAR
antibody hypofunction may have stronger impacts on specific
compartments of the affected microcircuitry.
Lastly, the integrated brain (micro-)circuits under investigation
here show complex emergent dynamics arising from a range of
often nonlinear interactions. This complexity can often give rise
Fig. 7 Pregnenolone sulphate increases glutamatergic transmission in NMDAR antibody infused rodent hippocampal slices in vitro and has similar
effects in human epilepsy brain tissue. a Representative whole-cell patch clamp recording of putative CA3 pyramidal cell sEPSCs from an NMDAR
antibody treated hippocampal slice before and after addition of PregS. Scale bar 10 pA vs. 5 s. b IEI of sEPSCS recorded from putative CA3 pyramidal cells
before and after PregS application to hippocampal slices prepared from NMDAR antibody treated animals at 48 h after Ab injection (n= 12 pairs of cells;
**p= 0.0093, Wilcoxon paired rank test) and after 7 day NMDAR antibody infusion (n= 6 pairs of cells; *p= 0.03, Wilcoxon paired rank test). The IEI of
sEPSCs recorded from CA3 pyramidal cells in control antibody slices are added for comparison (n= 7 cells; shown as open purple circles superimposed on
PregS bar). Statistical comparison between the three groups (NMDAR antibody vs. NMDAR antibody+ PregS vs. control) was significant at the 48 h
(p= 0.02, Kruskal–Wallis test) and 7 day timepoints (p= 0.01, Kruskal–Wallis test). c Representative in vitro whole-cell patch clamp recordings of sEPSCs
in human paediatric epilepsy before and after addition of PregS. Scale bar 10 pA vs. 5 s. d Amplitudes of sEPSCs recorded from cells in human brain tissue
before and after addition of PregS in vitro (n= 9 cells; p= ns (1), Wilcoxon ranked pairs test). e Interevent interval of sEPSCS recorded from cells in human
brain tissue before and after addition of PregS in vitro (n= 9 cells; ***p= 0.004, Wilcoxon ranked pairs test). Measurements expressed as mean median
(M) ± standard error of the mean (SEM).
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to unpredictable results, even where simple systems show a clear
mapping between excitation/inhibition balance and seizure pro-
pensity. Our modelling suggests that the effective synaptic con-
nectivity changes associated with NMDAR antibodies sensitise
the circuit to perturbations in another (largely unrelated) set of
parameters. This insight implies that whilst the seizure transition
may be indicative of a change in a balance of parameters asso-
ciated with excitation and inhibition, there may be territories of
parameter space where this change is tolerated without any
notable impact on the local field potential and other territories
where the same change of excitation/inhibition parameter balance
would produce large changes consistent with an epileptic seizure.
The simulations here indicate that the NMDAR antibody models
are much more sensitive to ‘ictogenesis’-associated parameter
changes, suggesting that the combined parameter changes
induced by NMDAR antibody have pushed the microcircuit into
a territory in parameter space, where it is particularly sensitive to
further perturbations.
Neurosteroids are derived from cholesterol and are precursors
to gonadal steroid hormones and the adrenal corticosteroids.
They are produced de novo by glial cells and principal neurons,
hence the term ‘neurosteroid’56, and modulate brain excitability
primarily by interacting with receptors and ion channels on the
membrane surface rather than within cells57. Pregnenolone
(precursor to PregS) elevates levels of allopregnanolone and
pregnenolone sulphate, a positive NMDAR receptor modulator.
Pregnenolone has been used as an effective adjunctive therapy in
treatment trials for schizophrenia, a psychiatric condition that
shares the pathophysiology of NMDAR hypofunction58–60. These
trials demonstrate both the safety and efficacy of Pregnenolone in
humans. In vivo, pregnenolone was found to reduce the hyper-
locomotion, stereotypic bouts and prepulse inhibition deficits in a
mouse model of schizophrenia acutely, and improved impaired
cognitive deficits with chronic treatment61. PregS, a sulfated ester
of pregnenolone, is a positive NMDAR modulator62,63 and stu-
dies show that the mechanism of action is to increase surface
expression of functional NMDARs containing the NMDAR
subunit subtype 2A (NR2A) or subtype 2B (NR2B), both the most
abundant subunits found in the brain; no evidence points to
changes in NR2C or NR2D subunits28. In a previous study, this
membrane delimited effect postulated to be via a non-canonical,
G-protein and calcium-dependent mechanism occurred within
10 min of application to cortical neurons, increasing surface levels
by 60–100%28; this speed of action of PregS was reproducible
in vitro in our brain slice recordings. In addition to the effect of
PregS on NMDARs, other CNS targets have been described,
including the GABAA receptor, glycine receptor, and more
recently the TRPM3 channel64 and Kir2.3 channel65. The effects
of PregS on the GABAAR most commonly described are at lower,
nanomolar range doses66,67. We found that the 100 µM dose of
PregS had no effect on GABAergic neurotransmission in the
brain slices from the NMDAR antibody model. A proconvulsant
effect was seen in the control antibody slices, but the reverse was
seen in the NMDAR antibody infused brain slices, suggesting that
it was the increase of NMDARs that led to the reduction in the
frequency of epileptic events.
Previous studies with NMDAR modulators and other treatments
have focused on the prevention of pathogenic antibody effects9–11.
To our knowledge this is the first study to show that symptoms
established for more than 48 h (in this case ictal activity in vitro), can
be treated with the use of the neurosteroid PregS. Whilst PregS was
chosen here specifically to treat the known underlying pathophy-
siology, its role for the treatment of epilepsy may extend into other
conditions or scenarios where the treatments that accord to the
notion of reestablishing excitation-inhibition balance have failed to be
effective (e.g. refractory status epilepticus)68.
We did not record directly from inhibitory interneurons but it
is likely that both cell types are involved in driving the epi-
leptogenesis. The CA3 network is highly complex, with CA3
pyramidal cells having convergent and divergent connections
with several interneuronal types in different hippocampal
regions69. A single CA3 pyramidal cell can make synapses with
30,000–60,000 neurons in the ipsilateral hippocampus70. It,
therefore, remains a possibility that NMDAR hypofunction
affecting GABAergic interneuronal populations produces a dis-
inhibited CA3 network55,71,72 and investigating this possibility
should be a goal of further electrophysiological studies.
Another limitation to this study was that the cognitive effects
of NMDAR antibodies were not investigated in the animals or
electrophysiologically through long-term potentiation (LTP)
recordings. However, LTP recordings will be difficult to interpret
with spontaneous ictal spikes as seen in these brain slices. It is
known that in CA3, NMDAR-dependent (associational-com-
missural, A-C fibres) and NMDAR-independent (Mossy-fibre)
forms of LTP are expressed in adjacent synapses. LTP has been
shown to be reduced by NMDAR antibody positive CSF
(experiments performed in Wistar rats), and this reduction may
contribute to the cognitive deficits seen clinically35. Mossy fibre
synapses display a markedly lower proportion of GluN2B-
containing NMDARs73 than associative or commissural synap-
ses, therefore a loss of NMDARs in this critical population of cells
could also be devastating. PregS offers an attractive treatment
strategy to increase NR1 and NR2B subunit NMDARs28 that
could potentially mitigate the short and long-term cognitive
effects seen in patients, as well as the seizures. Further detailed
molecular studies will need to be done to characterize the
NMDAR and subunit changes.
Future studies also need to focus on ascertaining the optimal
brain concentrations of the neurosteroid PregS in vivo in the
NMDAR antibody mediated disease models, and on determining
whether these can be achieved through direct administration of
PregS (e.g. by subcutaneous injection) or the precursor Pregne-
nolone (oral administration, a treatment already used safely in
humans)60. There is precedence for the use of neurosteroids in
other forms of epilepsy, including genetic epilepsies (e.g. Phase 3
clinical trial of ganaxolone in PCDH-19 female patients;
NCT03865732) as well as refractory status epilepticus74. In
genetic epilepsy, research efforts have focused for some time on
modifying the specific underlying genetic effect with new and
repurposed drugs75. In this study, we show that there is also a
possibility of providing receptor-specific neurosteroid treatment
to affected patents with immune-mediated epilepsy and
encephalitis.
Methods
NMDAR antibody and control antibodies. Three human-derived NMDAR
antibody preparations were obtained for experimental use. The first was NMDAR
antibody positive IgG prepared from plasma obtained, with informed consent at
plasmapheresis from a patient (11-year-old female with NMDAR antibody ence-
phalitis), using Protein G beads18. In brief, plasma was diluted 1:1 with Hartmann’s
solution and passed through Protein G sepharose column beads. To elute IgG,
0.1 M glycine solution (pH 2.3) was used and the sample then neutralized with 1M
Tris pH 8. A Coomassie Plus assay kit (Pierce, USA) was used to determine protein
concentrations of eluted fractions. Peak protein fractions were pooled and dialysed
against Hartmann’s solution, and IgG concentrated using Amicon ultra-4 10KDa
filter units, and then filter-sterilized. Nanodrop 3300 (ThermoScientific, UK) was
used to determine final IgG concentration (37 mg/ml). In addition, two different
recombinant NMDAR antibody specific human monoclonal antibodies were
donated for use; SSM5 (4.3 mg/ml)8 and 003-102 (3.4 mg/ml)3. Both of these
NMDAR antibody monoclonal antibodies have previously been shown to have
in vitro and in vivo pathogenic effects3,8.
Control antibodies (Control antibodies) were human derived IgG from one
healthy individual (healthy male, aged 35 years; concentration 30 mg/ml), and two
non-brain reactive monoclonal Control antibodies; mGO53 (514.5 µg/ml)3, and
12D7 (6 mg/ml)8.
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As all antibody preparations had previously been used in the studies specified
and were known to be pathogenic, and stocks for some preparations were limited, a
direct comparison was not made between each antibody preparation of the
epileptogenic effects. The three NMDAR antibody preparations will be collectively
referred to as “NMDAR antibodies” throughout the paper and the three control
preparations as “Control antibodies”. Detailed description of antibody use per
experiment is provided in Supplementary Table 1.
Animals. Given our experience in other rodent epilepsy models32,45, we hypo-
thesized that the use of juvenile male Wistar rats would increase the probability of
observing spontaneous seizures in a NMDAR antibody passive transfer model.
Thirty-one post-natal day 21 (P21) male Wistar rats, weighing 50–58 g, were used
for the in vitro experiments and 12 were used for the in vivo experiments. The
animals were housed in temperature- and humidity-controlled conditions with a
12 h/12 h light/dark cycle, and allowed to feed and drink ad libitum. All procedures
were compliant with current UK Home Office guidelines as required by the Home
Office Animals (Scientific Procedures) Act 1986. They were carried out under the
authority and procedural approval of a UK Home Office approved project license
and in line with ARRIVE guidelines. Local ethical approval for the study was
granted by the Aston Bioethics Committee, University of Aston, Birmingham, UK.
Surgery: stereotaxic ICV injection of NMDAR- and control antibodies. ICV
injection was performed under isoflurane anaesthesia with rats fixed in a stereo-
taxic frame18. A 0.5 cm incision was made caudally over the skull surface which
was then exposed before a single burr hole was made for ICV injection. The co-
ordinates for the left lateral ventricle were 1.5 mm left lateral and 0.6 mm caudal
from bregma76. 10 micrograms (10 mcg) of SSM5 (NMDAR antibody monoclonal
antibody), or non-reactive control antibody (12D7) or 8 μL of NMDAR antibody
IgG18 or healthy control IgG was used. Antibody preparations were coded to allow
for blinded analysis. The antibody was injected over twenty minutes using a
Hamilton syringe with 33 gauge needle to a depth of 3.2 mm from skull surface.
Following injection, the syringe was left in place for ten minutes before being
withdrawn over twenty minutes. The skin was sutured and animal allowed to
recover before being replaced in home cage.
Local field potential (LFP) recordings. Forty-eight hours after ICV injection or at
the end of the recording period in telemetry experiments, rats were anaesthetized
using isoflurane followed, after loss of consciousness, by pentobarbital (60 mg/kg,
SC) and xylazine (10 mg/kg, IM). Transcardial perfusion was then performed using
ice-cold artificial cerebrospinal fluid (cutting aCSF) in which NaCl had been
replaced with equimolar sucrose. Animals were decapitated, and the brain was
removed and placed in ice-cold cutting aCSF. Sagittal slices at 450μm were cut
using a vibratome (Campden Instruments, UK)77. The slices were transferred to a
storage chamber containing standard aCSF (in mM: 125 NaCl, 3KCl, 1.6 MgSO4,
1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 10 glucose) and constantly bubbled with
carbogen (95% O2/5% CO2) at room-temperature for at least one hour prior to
recording. Slices were then transferred to an interface chamber (Scientific System
Design Inc., Canada) and continuously perfused with aCSF (2–3 ml/min) main-
tained at 30–31 °C and visualised with a SZ51 stereomicroscope (Olympus). A
Flaming-Brown micropipette puller (Sutter Instruments, CA) was used to pull
borosilicate glass microelectrodes with an open tip resistance of 1–3MΩ when
filled with aCSF. Electrodes were inserted into CA3 and CA1 regions of the hip-
pocampus using Narishige MM-3 (Narishige, Japan) micromanipulators and sig-
nals were recorded using an EXT-02 headstage and amplifier (NPI Electronic).
HumBugs (Quest Scientific) were used to remove electrical 50 Hz interference from
recordings. The signal was then amplified ×100 via an EX10-2F amplifier (NPI
Electronics) and filtered (700 Hz low-pass, 0.3 Hz high-pass, sampling rate 5 kHz)
and further amplified ×10 using a LHBF-48X amplifier (NPI Electronics). Signals
were then digitised at 10 KHz using an analogue to digital converter (Micro-1401-
II; CED). LFP recordings were assessed using Spike2 software (CED) for sponta-
neous epileptiform activity. Spike2 was used to calculate the root mean square
(RMS) amplitude of each recording. Epileptiform activity was classified as an event
when it displayed an amplitude greater than four-fold the RMS amplitude, pro-
viding the event count, while the time difference between these events provided the
interevent interval. A custom MATLAB script was used to prevent false event
detection, removing those with an interevent interval less than 15 ms. Statistical
analysis was conducted using Graphpad Prism 8 (GraphPad Software Inc), sta-
tistical tests used to compare groups (Mann-Whitney) were one-tailed. Measure-
ments were expressed as mean (M) ± standard error of the mean (SEM).
Whole-cell patch clamp recordings. For whole-cell patch clamp recordings, brain
slices were prepared as above but sliced at a thickness of 350 µm. For recording, the
slices were transferred to a submerged chamber (Scientifica, UK) and visualised
using Nomarski infra-red optics on a BX51WI Microscope (Olympus). A Flaming-
Brown micropipette puller (Sutter Instruments, USA) was used to pull borosilicate
glass microelectrodes of 4–6MΩ for recordings. For voltage clamp recordings,
electrodes were filled with an internal solution containing (in mM): 100 CsCl, 40
HEPES, 1 Qx-314, 0.6 EGTA, 5 MgCl2, 10 TEA-Cl, 4 ATP-Na, 0.3 GTP-Na and 1
IEM 1460 (titrated with CsOH to pH 7.25) at 290–295 mOsm for IPSCs. For EPSCs
the internal solution contained (in mM): 40 HEPES, 1 Qx-314, 0.6 EGTA, 2 NaCl,
5 Mg-gluconate, 5 TEA-Cl, 10 Phospho-Creatinine, 4 ATP-Na, 0.3 GTP-Na
(titrated with CsOH to pH 7.3) at 285 mOsm for EPSCs. The EPSCs and IPSCs
were recorded as apparent inward currents at −70 mV using an Axopatch 200B
amplifier (Molecular Devices, USA). Signals were low-pass filtered at 5 kHz with an
8-pole Bessel filter and digitised at 10 kHz using a Digidata 1440 A and pClamp
software (Molecular Devices). For intrinsic cell excitability experiments, whole-cell
current-clamp recordings were made from hippocampal neurons using an Axo-
patch 700 series amplifier (Molecular Devices, USA) and with a K-gluconate-based
intracellular solution containing (in mM) K-gluconate (120) hepes (40) KCL (10)
Na2ATP (2) Na-GTP (0.3) MgCl2 (3) EGTA (0.5). Membrane potential was
manually adjusted when required to −60 mV by continuous somatic current
injection. Membrane response and action potential firing were measured by
applying depolarizing steps of current (duration of 1 ms at 10pA increments). For
spike/current intensity curves, the number of action potentials was plotted against
the injected current. Input resistance was measured from the slope of a linear
regression fit to the voltage–current plotted graph between −80 pA to 0 pA. Data
were analysed using Axograph and Prism 8, statistical tests used to compare groups
(Mann–Whitney and Wilcoxon matched pairs ranked tests) were one-tailed.
Measurements are expressed as mean median ± SEM.
For human tissue recordings, brain slices were prepared as above using choline-
based artificial cerebrospinal fluid78,79. Briefly, human tissue was obtained with
informed parental or guardian consent from paediatric patients prior to them
undergoing epilepsy surgery at Birmingham Children’s Hospital. Ethical approval
was obtained from the Black Country Local Ethics Committee (10/H1202/23; 30
April 2010), and from Aston University’s ethics committee (Project 308 cellular
studies in epilepsy) and through the Research and Development Department at
Birmingham Children’s Hospital (IRAS ID12287). Brain tissue was obtained from
7 patients (F:M 4:3), median age 6 years (range 4–16 years). Surgical procedures
included frontal resection (three), temporal parietal occipital disconnection (one),
temporal lobectomy (two), and right hemispherectomy (one) as described in
Supplementary Table 2. Specimens were resected intraoperatively with minimal
traumatic tissue damage, and minimal use of electrocautery. Brain tissue was
transported in ice-cold choline-based artificial CSF as previously described79.
Drugs. For all in vitro electrophysiology experiments, Pregnenolone sulphate
(Sigma, UK) was prepared as 1 M stock using dimethyl sulfoxide (DMSO). A
concentration of 100 µM was used for all electrophysiology experiments. MK-801
(Hello Bio, UK) was prepared with distilled water as 10 mM stock and used at
10 µM concentrations.
Immunofluorescence and image analysis. Following in vitro electrophysiology
experiments, brain slices were briefly fixed in 4% paraformaldehyde (PFA) for
45 min. To determine NMDAR antibody or control antibody binding, the sections
were rinsed with phosphate-buffered saline (PBS) and then incubated in anti-
human IgG Alexa-Fluor-488 at 1 in 1000 (Invitrogen, UK) overnight at 4 °C.
Sections were washed and mounted with aqueous mounting medium containing
DAPI. Images of hippocampal sections were taken on a Tandem Confocal Scan-
ning SP5 II microscope (Leica Microsystems Ltd) using a (10×/0.30) dry objective
lens. Fluorescence was excited with a 488 nm argon laser at 23% power (emission
bandwidth 504nm-564nm). Confocal micrographs were acquired at 1024 pixels2
with actual area of 1.48mm2, and scanning speed 100 Hz.
Biocytin (Sigma, UK) was added to the electrode filling solution at a
concentration of 5 mg/ml to determine the characteristics of the recorded cell
during whole-cell patch clamp experiments. Neurons were filled with biocytin and
slices were fixed overnight at 4 °C in 100 mM PBS (pH 7.3) containing 4% PFA
(BDH, USA). After washing in PBS, slices were incubated for 18 h in PBS
supplemented with 1% Triton X-100 and 0.2% streptavidin Alexa Fluor 488
conjugate (Invitrogen) at 4–6 °C. Sections were washed and mounted with aqueous
mounting medium containing DAPI for imaging.
Fluorescent intensity Log EC50 ratio of hippocampal sections was determined
using 5 regions of interest (ROI) of the same size from the molecular outer layer
and from the granular cell layer of CA3. The mean fluorescent intensity Log EC50
value of the outer molecular layer was normalised by dividing it by the mean
fluorescent intensity Log EC50 of nonspecific staining in the granular cell layer.
This process provided a ratio for each replicate. All images were analysed through
FIJI by converting them to grayscale (8-bit) before generating cumulative pixel
intensity histograms for each ROI which were calculated using a customized macro
programme1,18. Any statistical analysis performed was conducted in GraphPad
Prism 8.
Surgery: placement of ventricular catheters, osmotic pumps and wireless EEG
transmitters. Osmotic pumps (model 1007D, Azlet) were used for cerebroven-
tricular infusion of monoclonal antibodies and human IgG (volume 100 µl, flow
rate 0.5 µl, duration 7 days)7,8. Two osmotic pumps per animal were prepared by
loading with monoclonal antibodies or human IgG and then connected to poly-
ethylene tubing 69 mm-×-1.14 mm diameter (C312VT; PlasticsOne) and a double
osmotic pump connector intraventricular cannula (328OPD-3.0/SPC; PlasticsOne).
Pumps were left overnight in sterile saline solution at 37 °C. Rats were placed in a
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stereotaxic frame for surgery performed under isoflurane anaesthesia. Osmotic
pumps were placed subcutaneously and attached cannulae inserted into both lateral
ventricles (1.5 mm lateral, 0.6 mm caudal). The EEG transmitter was placed in a
subcutaneous pocket formed over the right flank with a single skin incision and
blunt tissue dissection (A3028B-DD subcutaneous transmitters, 90-mm leads,
OpenSource Instruments (OSI)), and depth electrode (W-Electrode (SCE-W), OSI)
placed in the left hippocampus (CA3, 3.5 mm lateral, 3.6 mm caudal, depth
2.3 mm) with a reference electrode implanted on the contralateral skull surface
(3.5 mm lateral, 3.6 mm caudal). The cannula and skull electrodes were secured
with dental cement18,25.
Collection and analysis of EEG data. EEG data (wide band pass 0.2–160 Hz
sampled at 512 samples per second) was collected and recorded from freely moving
animals placed in a custom-built Faraday cage with an aerial. Transmitter signals
were continuously recorded using Neuroarchiver software (OSI) and analysed as
previously described18,25,80. In brief, for automated ictal event detection, video-
EEG matching was used to identify ictal EEG events. The Event Classifier (OSI)
was then used to classify one-second segments of EEG according to program
metrics (power, coastline, intermittency, coherence, asymmetry, spikiness) enabling
similar events to cluster together when plotted. This generated a library of ictal
events that allowed fast identification of abnormal EEG events by automated
comparison to the library (http://www.opensourceinstruments.com/Electronics/
A3018/Seizure_Detection.html). Powerband analysis was carried out using a
custom-designed macro. Statistical analysis was conducted using Graphpad Prism
8 (GraphPad Software Inc.).
Statistics and Reproducibility. Data in each graph was analysed with two-way
ANOVA and post-hoc test, Mann–Whitney or Wilcoxon paired rank test,
specified in figure legend. In in vitro electrophysiology experiments, individual
points represent brain slices or cells recorded from at least three different ani-
mals or human brain tissue samples per experimental group. In in vivo
experiments, data were collected from six animals in each group. The repro-
ducibility of the data were maintained by using different NMDAR-Ab pre-
parations. All graphs are expressed a mean (M) with bars representing standard
error of the mean (SEM).
Dynamic causal modelling. Dynamic causal modelling (DCM) was performed
using the academic software package SPM12 (https://www.fil.ion.ucl.ac.uk/spm/).
All analysis code and raw data are available online at https://doi.org/10.17605/
OSF.IO/GUPBF81. Analogous to previous work21,82, we modelled LFP spectra
recorded in rat hippocampal tissue as arising from a single canonical microcircuit
at steady state83. This ‘canonical microcircuit’ is a layered set of recurrently coupled
excitatory and inhibitory neural masses84–86. Originally conceived as a description
of layered cortical population activity, the canonical microcircuit model has also
been shown to offer a parsimonious explanation of rodent hippocampal activity in
different physiological and abnormal states87. The four populations of the cano-
nical microcircuit act as two coupled oscillator pairs: One superficial oscillator
typically characterised by fast (beta/gamma-range) frequencies and consisting of
‘superficial pyramidal cells’ and ‘spiny stellate cells’; and one deep oscillator with
typically slow (theta/alpha-range) frequencies consisting of inhibitory interneurons
and deep pyramidal cells. This model is a description of neuronal interactions at
the population level. Effective synaptic connectivity is parameterized by three key
parameters: effective coupling strength (γ), a postsynaptic time constant (τ), and
the slope of a parameterised sigmoid function (σ) that encodes population response
variance88. The free neuronal parameters in the model implemented here are
summarized in Table 1.
DCM employs a standard variational Laplace model inversion to (i) estimate
posterior densities of model parameters given the data and some prior values, and
(ii) provide an estimate for the Bayesian model evidence using the free energy
approximation89,90. Initial parameter values were taken from the standard
formulation of the canonical microcircuit in dynamic causal modelling originally
derived from cat visual cortex recordings27,84. These were adapted to this particular
experiment in a two-stage approach—posterior expected values from an initial
model fit to the baseline data were subsequently used as priors in the subsequently
fitted conditions. These priors do not define absolute limits to the parameter ranges
but restrict excessive between-condition differences through Bayesian integration
of prior estimates (‘the priors’) and empirical likelihoods (‘the data’) to generate
posterior densities (‘parameter estimates’)91.
The estimation of the Bayesian model evidence allowed us to compare evidence
for models of the same data under different assumptions encoded in different
priors. Specifically, we wished to test the hypothesis that NMDAR antibody-
induced changes measured using whole-cell patch clamp recordings contribute to
the LFP features observed in vivo and that were modelled with the DCM. To test
this hypothesis, we, therefore, performed several DCM inversions on the same data
under quantitatively different priors, and compared the model evidence for each of
these models.
Specifically we followed the following procedure; we first wanted to identify
which synaptic parameters we would expect to be altered in the NMDAR antibody
in vivo experiments, based on the microscale in vitro recordings. To be able to
make quantitative predictions about such parameters we quantified relevant
features of synaptic transmission in whole-cell patch clamp recordings. Using these
features, we generated quantitative predictions of synaptic parameter differences
between control antibody and NMDAR antibody conditions. To be able to infer
synaptic coupling parameters underlying the local field potential data, we extracted
data from different relevant conditions and states (i.e. interictal control antibody,
interictal NMDAR antibody, and ictal NMDAR antibody) to then fit the
microcircuit models using DCM to the average power spectral densities of each of
these conditions. We next wished to identify a synaptic parameter combination
that best describes a physiological, interictal state from which all other conditions
emerge by changes in synaptic coupling. We, therefore, fitted a single canonical
microcircuit model to control antibody data, using the inferred parameters as
priors in subsequent Bayesian model inversions in the next steps. To address the
question whether the observed microscale changes in synaptic function contribute
to the observed LFP features, we fitted a single canonical microcircuit to interictal
NMDAR antibody data under different sets of priors—including those that are
informed by microscale data, and those that are not. This allowed us to perform
Bayesian model comparison between these models. Here we would expect models
that contain microscale-derived prior information to outperform other models if
the modelled microscale features contribute to the LFP data. To address the
question which synaptic mechanisms best explain condition- and state-differences,
we fitted a single canonical microcircuit to seizure NMDAR antibody data, then
quantified the parameter differences between different DCM models. The objective
here was to quantify the main differences between conditions (control antibody vs
NMDAR antibody) and states (interictal vs. seizure) in terms of neuronal
population model parameters.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The supportive data for this study are available within the manuscript and the
Supplementary Information. All source data underlying figures are presented in
Supplementary Data 1. All dynamic causal modelling raw data are available online at
http://doi.org/2010.17605/OSF.IO/GUPBF. Requests should be made to the
corresponding authors for materials, dependent on stock availability.
Code availability
Code for data analysis for dynamic causal modelling (Figs. 4, 5) can be found here http://
doi.org/2010.17605/OSF.IO/GUPBF.
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Table 1 Free parameters fitted by the DCM (parameters related to NMDAR-transmission in bold).
τ1 (spiny stellate time constant) γ1 (ss to ii excitation)
τ2 (inhibitory interneuron time constant) γ2 (dp to ii excitation)
τ3 (superficial pyramidal cell time constant) γ3 (ss to sp excitation)
τ4 (deep pyramidal cell time constant) γ4 (sp to ss inhibition)
σ (population response variance) γ5 (ii to ss inhibition)
γ6 (ii to ip inhibition)
γ7 (sp inhibitory self-modulation)
γ8 (ii inhibitory self-modulation)
γ9 (ss inhibitory self-modulation)
γ10 (dp inhibitory self-modulation)
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